Impact of Three Anti-TNF[alpha] Biologics on Existing and Emergent Autoimmunity in Rheumatoid Arthritis and Spondylarthropathy Patients

The objective of this study was to analyze the effects of 3 anti-TNF[alpha] agents on markers of autoimmunity in rheumatoid arthritis (RA) and spondylarthropathy (SPA) patients. First-time anti-TNF[alpha] biologics (infliximab, etanercept, or adalimumab) were prescribed to 156 RA and 95 SPA (58 anky...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical immunology 2008-09, Vol.28 (5), p.445
Main Authors: Bacquet-deschryver, H, Jouen, F, Quillard, M, Ménard, J F, Goëb, V, Lequerré, T, Mejjad, O, Daragon, A, Tron, F, Le Loët, X, Vittecoq, O
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of this study was to analyze the effects of 3 anti-TNF[alpha] agents on markers of autoimmunity in rheumatoid arthritis (RA) and spondylarthropathy (SPA) patients. First-time anti-TNF[alpha] biologics (infliximab, etanercept, or adalimumab) were prescribed to 156 RA and 95 SPA (58 ankylosing spondylarthritides, 37 psoriatic arthritides). During 1-2 years of follow-up, clinical, biological [antinuclear (ANA) and anti-double-stranded (dsDNA) antibodies, rheumatoid factors (RF), and anti-cyclic citrullinated peptide (CCP) for RA], and therapeutic data were collected biannually. ANA appeared or ANA and anti-dsDNA titers increased significantly (P
ISSN:0271-9142
1573-2592
DOI:10.1007/s10875-008-9214-3